Holen Sie sich die Stockscreener-App
12.36
1.90%
-0.24
Handel nachbörslich:
12.47
0.11
+0.89%
Schlusskurs vom Vortag:
$12.60
Offen:
$12.63
24-Stunden-Volumen:
1.65M
Relative Volume:
0.38
Marktkapitalisierung:
$1.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-313.94M
KGV:
-3.5254
EPS:
-3.506
Netto-Cashflow:
$-284.57M
1W Leistung:
-5.43%
1M Leistung:
-21.77%
6M Leistung:
+63.49%
1J Leistung:
+205.19%
1-Tages-Spanne:
$12.30
$12.80
1-Wochen-Bereich:
$12.07
$13.63
52-Wochen-Spanne:
$1.50
$16.33
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
12.36 | 1.16B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Herabstufung | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-04-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before October 5, 2026 - ACCESS Newswire
REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Class Action Filed Against Replimune Group, Inc. (REPL) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
Securities Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Represents Shareholders - accessnewswire.com
Howard G. Smith joins probe into Replimune fraud after FDA BLA rejection - scanx.trade
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - accessnewswire.com
Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026Contact Levi & Korsinsky - accessnewswire.com
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug - Stocktwits
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission. - Pluang
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - prnewswire.com
Replimune stock falls 3.79 percent as losses persist - AD HOC NEWS
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on October 5, 2026 - ACCESS Newswire
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - prnewswire.com
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Replimune stock gains as share authorization doubles - AD HOC NEWS
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 5, 2026 Deadline - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors - GlobeNewswire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Replimune Group Inc (NASDAQ: REPL) Share Price, REPL Stock News, REPL Share Price & Updates - kalkine.com.au
Replimune Group, Inc. (REPL) Stock Analysis: A Potential 51.52% Upside In Biotech Innovations - DirectorsTalk Interviews
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026 - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Replimune shares plunge 84% after FDA rejects R... - Pluang
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors With Losses May Contact SueWallSt - PR Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - prnewswire.com
REPL Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors – Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Stock DropRobbins LLP Reminds Investors They May Be - GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class ActionContact Levi & Korsinsky - Business Wire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL: TUDRIQEV launch targets rapid adoption in key accounts, with expansion and new indications ahead - TradingView
DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of - GlobeNewswire
Replimune faces class action over alleged nondi... - Pluang
Replimune at cantor healthcare conference: careful launch, broad pipeline By Investing.com - Investing.com Canada
REPL Investor Alert: Replimune Group, Inc. Securities Class Action NoticeContact SueWallSt - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - prnewswire.com
Class action lawsuit filed against Replimune fo... - Pluang
Replimune faces securities lawsuit over alleged misleading FDA trial data claims, stock plunged 84%. - Pluang
REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - Morningstar
Replimune Group Stock Short Interest Falls to 43.08% - moomoo.com
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):